报价延迟最少15分钟:2026/04/15 09:30 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.5 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.81/-7.44
|
|
企业价值
33.10M
|
| 资产负债 |
|
每股账面净值
2.82
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
299.06K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitiveconditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing. |
